Trial · NCT07465757
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
NCT07465757, Phase 2, Recruiting, Puma Biotechnology, Inc.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC). Trials, record NCT07465757. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07465757
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
- NCT number
- NCT07465757
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Puma Biotechnology, Inc.
- Conditions
- Small Cell Lung Cancer ( SCLC )
- Interventions
- Alisertib, Alisertib, Alisertib, Alisertib, Alisertib, Paclitaxel
- First posted
- 2026-03-12
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants with Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events) | From date of first dose through last dose plus 28 days, assessed up to 24 months | Treatment emergent adverse events are those events reported on or after the first dose of investigational product and up to 28 days after the last dose. |
| Secondary | Objective Response Rate (ORR) | From date of first dose to first confirmed Complete or Partial Response, assessed up to 24 months | ORR is defined as the proportion of participants demonstrating a confirmed Complete or Partial Response during the treatment phase of the study. |
| Secondary | Duration of response (DOR) | From start date of response to first PD or death, assessed up to 24 months | DOR is measured from the time at which measurement criteria are first met for confirmed Complete or Partial Response (whichever status is recorded first) until the first date of recurrence or progressive disease (PD) or death is objectively documented. |
| Secondary | Disease Control Rate (DCR) | From date of first dose to first confirmed Complete or Partial Response, whichever came earlier, assessed up to 24 months | DCR is defined as the proportion of patients who achieve overall tumor response (confirmed Complete or Partial Response) or Stable Disease lasting for at least 12 weeks from first dose of investigational product. |
| Secondary | Progression Free Survival (PFS) | From date of first dose to date of recurrence, progression or death, assessed up to 24 months | PFS is measured in months and based on the local tumor assessment. The time interval from the date of first dose until the first date on which recurrence, progression, or death due to any cause, is documented. |
| Secondary | Overall Survival (OS) | From date of first dose to death, assessed up to 24 months | OS is defined as the time from date of first dose to death due to any cause, censored at the last date known alive on or prior to the data cutoff employed for the analysis, whichever was earlier. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07465757
GET https://conductscience.org/api/trials/v1/NCT07465757/registered